Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease that affects an estimated 2 million people in the United States and an estimated 20 million individuals worldwide. The RA treatment market has undergone significant changes over the past 5-10 years with the introduction of biologic, Disease Modifying Antirheumatic Drugs (DMARDs) - specifically, the Tumor Necrosis Factor-alpha (TNF-α) class of protein therapeutics. Products such as Enbrel (etanercept), Remicade (infliximab), and Humira (adalimumab) have established themselves as the standard of care in RA patients failing to respond to conventional DMARDs and in turn have generated significant financial windfalls for their developers and marketers.
The success of the TNF-α class of therapeutics, in conjunction with the large patient population they address, has created an explosion in R&D activity for new biologic and small-molecule treatments. As of January 2009, Austin Research Group has identified and is tracking 96 active programs in clinical trials.
Austin Research Group' s Therapeutic Clinical Intelligence (TCI) report provides clients with an exhaustive compilation and in-depth assessment of the entire clinical R&D competitive landscape for RA therapeutics.
This TCI report is the most comprehensive assessment of the RA competitive landscape published to date. The report contains more than 300 pages of detailed intelligence, analysis, and commentary on the clinical profiles 96 active RA programs from market to phase 1 that have the potential to alter the market dynamics in RA over the next 5-10 years.
This actionable deliverable captures detailed intelligence on competitive clinical programs in a ready-to-use format, enabling fast analysis without wading through voluminous text and white space common in other therapeutic area publications.